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ABSTRACT 
The potential association between sickle cell trait (SCT) and increased arterial 
stiffness/blood pressure (BP) has not been evaluated in detail despite its 
association with stroke, sudden death and renal disease. We performed 24-
hour ambulatory BP monitoring and arterial stiffness measurements in 
adolescents raised in a malaria free environment in Kenya.  
Between December 2015 and June 2016, 938 randomly selected adolescents 
that had been continuous residents of Nairobi from birth were invited to 
participate in the study. Standard clinic BP measurement was performed 
followed by 24-hour ambulatory BP monitoring and arterial stiffness 
measurement using an Arteriograph device. SCT status was determined 
using DNA genotyping on contemporaneously collected blood samples. Of 
938 invited, 609 (65%) provided complete data for analysis. SCT was present 
in 103 (17%). Mean 24-hour systolic and diastolic BP, SD was (116, 11.5) and 
(64, 7) mmHg respectively in SCT; and (117, 11.4) and (64, 6.8) in non-SCT. 
Mean pulse wave velocity (PWV), SD was (7, 0.8) and (7, 0.8) ms-1 
respectively in SCT and non-SCT. No differences were observed in PWV and 
any clinic or ambulatory BP derived measures between those with and 
without SCT. These data suggest that SCT does not independently influence 
BP or PWV.  
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The sickle cell trait (SCT), common among populations of African descent(1) 
due to the protection it offers against malaria(2-4), has been associated with 
increased risk of cardiovascular and renal disease.(5-8) However the 
underlying mechanisms of this increased risk have not been elucidated 
clearly, hampering measures that can be implemented to reduce risk in 
carriers. 
Individuals of African descent have relatively higher blood pressure (BP) 
compared to other ethnicities (9), and it is conceivable that increased BP or 
arterial stiffness, which have been shown to precede clinical events similar to 
those seen in SCT, could precede the events observed in SCT carriers.(8, 10, 
11) Alternatively increased arterial stiffness and BP in individuals with SCT 
could result from the yet to be elucidated mechanisms that lead to 
cardiovascular and renal events.  
Previous studies that assessed BP and/or arterial stiffness in individuals with 
SCT had several weaknesses; Rossi-Espagnet et al in a study conducted in 
Colombia in 1968 found no difference in BP between individuals with and 
without SCT.(12) However, BP measurements were performed only once at 
home visits; there was a poor response rate in men; and the data were 
susceptible to confounding by malaria, which SCT protects against(2-4) and is 
possibly related to BP.(13, 14) Bayramoglu et al found similar arterial stiffness 
indices in young Turkish adults with and without SCT, but the sample size 
was small.(15) Although the studies demonstrating increased cardiovascular 
and renal disease risk in SCT assessed BP at baseline, the BP 
measurements were done in the clinic/office, using manual or automated 
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methods.(7, 8) None of these studies utilized 24-hour ambulatory blood 
pressure monitoring (ABPM), considered the reference method for BP 
measurement(16, 17), raising the possibility that subtle but significant 
differences in BP could have been missed.(17) ABPM overcomes many of the 
limitations of office/clinic BP measurement.(17) ABPM also enables detection 
of masked hypertension (normal clinic BP but elevated 24-hour BP), a 
cardiovascular risk factor(18) that is more common in populations of African 
descent(19), the same population that has a high prevalence of SCT.  
If arterial stiffness and/or BP are increased in young individuals with SCT they 
could become the target of interventions aimed at reducing future 
cardiovascular and renal events. We conducted a population-based study in 
Nairobi, Kenya to determine whether SCT influences arterial stiffness and BP 
among adolescents who have had minimal exposure to malaria.  
METHODS 
The study was a cross-sectional sample of residents of the Nairobi Urban 
Health and Demographic Surveillance System (20) in Kenya conducted from 
December 2015 to June 2016. The area has a population of approximately 
70,000 and the prevalence of hypertension is high.(21) Nairobi, the capital city 
of Kenya was chosen for this study because of 2 reasons: First, Nairobi is 
located at high altitude (1800 meters above sea-level) and there is no 
evidence of malaria transmission.(22) This made it possible to study the effect 
of SCT on BP unconfounded by the presence of malaria. This was necessary 
because malaria could influence BP(14) and at the same time SCT protects 
against malaria(3, 4); Second, the population of Nairobi is composed of ethnic 
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groups originating in all parts of the country including those whose ancestral 
lands were endemic for malaria (e.g. Luhya, Luo, Teso, Mijikenda). The sickle 
cell gene frequency is much higher among these ethnic groups.(23) In order 
to increase our efficiency in recruiting participants with SCT we limited our 
recruitment to those who identified themselves as genetically derived from 
one of these ethnic groups.  
Population-wide censuses are conducted 4 times a year within the study 
area.(20) Using census data we selected all children currently aged 11-17 
years who had a continuous record of residence in the area since birth. 
Continuous residency was a requirement so as to minimize potential 
exposure to malaria as a result of migration. Trained staff visited all subjects 
who had been selected to participate in the study at their homes. Parents of 
the children were then asked to bring them to the nearer of two study clinics 
within the area to undergo study procedures. Subjects who failed to come to 
the clinic within 3 months of being requested to do so were considered to 
have refused to participate in the study.  
Subjects first underwent an interview where they answered questions about 
their past medical history and their socioeconomic status based on the multi-
dimensional poverty index.(24) Weight and height were measured using a 
validated SECA 874™ weighing machine and a portable stadiometer (SECA 
213™) (SECA GMBH, Hamburg, Germany), respectively. Mid-upper arm 
circumference was measured in a standardized manner using TALC™ 
(Teaching Aids at Low Cost, Hertfordshire, UK) tapes. We then took a 
screening BP measurement using a validated automated Omron™ M10-IT 
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(Omron Healthcare Europe B.V, Hoofddorp, The Netherlands) BP machine. 
An appropriately sized cuff was placed on the non-dominant arm after the 
subject had been seated for at least 5 minutes. Three BP measurements 
were taken over a 5-minute period and the mean of the last 2 measurements 
was recorded as the screening BP value. All participants were subsequently 
fitted with an Arteriograph24™ device (Tensiomed Ltd, Budapest, Hungary) 
for 24-hour ABPM as well as pulse wave velocity (PWV) determination.(25) 
The devices, which have been calibrated in children(26), were programmed to 
take measurements every 20 minutes during daytime hours (0600-2200 hrs) 
and every 40 minutes at night (2200-0600 hrs).  
Laboratory procedures 
We collected 10ml of blood from participants for full blood count, 
determination of sickle hemoglobin status and serum electrolytes. After 
performing automated full blood counts using an ACT 5™ machine (Beckman 
Coulter Inc, Brea, CA), whole blood samples were frozen at -80ºC and then 
transported to the KEMRI-Wellcome Trust Research Programme laboratories 
in Kilifi, Kenya for determination of sickle hemoglobin status. DNA was 
extracted retrospectively from the frozen samples by use of Qiagen™ DNA 
blood mini-kits (Qiagen, Crawley, United Kingdom) and typed for sickle 
hemoglobin using polymerase chain reaction.  
Serum and urine samples collected from participants were frozen at -80ºC 
within 4 hours of collection and later transported to Kilifi, Kenya for analysis. 
We determined sodium and potassium, urea and creatinine levels in these 
samples using ion electrophoresis and the jaffe method, respectively.(27) We 
additionally determined albumin levels in the urine samples by 
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immunoturbidometry using a Quantex™ microalbumin kit (Instrumentation 
Laboratory, Barcelona, Spain). 
Statistical methods 
Based on an expected minimum prevalence of 10% SCT in the ethnic groups 
we were studying, a systolic BP standard deviation of 15 mmHg, and 30% 
attrition due to poor quality ABPM data, we estimated that a total of 550 
participants would provide 80% power to detect half of a standard deviation 
(7.5 mmHg) difference in 24 hour systolic BP between individuals with and 
without SCT. 
As there are no published criteria for acceptable ABPM data in children, we 
used guidelines for completeness of ABPM data in adults from the 
International Database of Ambulatory blood pressure in relation to 
Cardiovascular Outcomes study.(28) Specifically, ABPM data were 
considered of acceptable quality if they met the following criteria: minimum 10 
daytime and minimum 5 nighttime readings, where day was defined as 1000-
2000 hrs and night as 0000-0600 hrs.(28) The same time periods were used 
to determine average daytime and nighttime blood pressures and to evaluate 
dipping status. Time weighting was applied in calculating average BP values 
for all time periods.(29)  
We defined screen positives for hypertension as individuals whose mean of 
the last 2 clinic BP measurements was above the 95th percentile for their age, 
sex and height.(16) Confirmed hypertensives were those whose 24hr systolic 
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and/or diastolic BP averages respectively were above the 95th percentile for 
their sex, age and height.(16)  
We categorized all subjects who were not on anti-hypertensive medication 
using the combination of clinic BP measurements and ABPM into four 
categories: sustained hypertensives (screen positive and confirmed 
hypertensive on ABPM); white coat hypertensives (screen positive, not 
confirmed hypertensive on ABPM); masked hypertensives (screen negative, 
confirmed hypertensive on ABPM) or normotensives (screen negative, not 
confirmed hypertensive on ABPM).(30)  
Dipping status was defined using ABPM data only, using day and night 
periods as defined above. Subjects were classified using the following four 
categories, based on the night/day ratio of mean systolic and/or diastolic BPs: 
rising or absence of dipping (ratio ≥1.0); mild dipping (0.9 < ratio ≤1.0); 
dipping (0.8 < ratio ≤ 0.9); and extreme dipping (ratio≤0.8).(31) 
Estimated glomerular filtration rate was calculated using the Schwartz 
formula.(32) 
Summary statistics computed included means, medians and proportions as 
appropriate. Comparisons between SCT carriers and non-carriers were made 
using Student’s t-test and χ 2 tests as appropriate. Data that were not 
normally distributed were log transformed prior to analysis. We compared 
ABPM and arterial stiffness measures between those with and without the 
sickle cell trait by Student’s t-test. In addition we performed a multivariate 
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regression analysis testing the effect of sickle carrier status on mean 24-hour 
systolic and diastolic BP with sex, age, body mass index, pulse wave velocity 
and estimated glomerular filtration rate as covariates.  
All analyses were conducted using Stata™ Version 12 software (College 
Station, Texas). 
The Kenya Medical Research Institute’s Ethical Review Committee approved 
the study. Written informed consent was obtained from parents of study 
participants. Participating children also provided written assent. The 
corresponding author had full access to all the data in the study and takes 
responsibility for the integrity of the data and the accuracy of the data 
analysis. 
RESULTS 
Of the 938 subjects requested to participate in the study, 686 (73%) 
completed enrollment (Figure 1). The 252 adolescents that were not recruited 
into the study were 0.6 years (95% CI 0.3-0.9) older than study participants, 
but with a similar sex distribution (53% female) to those that participated in 
the study. Genotype data was available for 644 subjects, 609 (95%) of who 
had complete ABPM data. Sickle cell trait (SCT) was present in 103 (15%) of 
participants. The proportion of participants with complete ABPM data did not 
differ by sickle cell trait (91% vs 90%, p=0.817) or any of the other 
demographic and clinical data collected. One participant had Sickle Cell 
Disease (Hemoglobin SS) and was dropped from analyses. None of the 
participants were previously aware of their sickle carrier status.  
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Mean clinic BP, SD among all participants was (98, 11) mmHg systolic and 
(64, 8) mmHg diastolic. The mean 24-hour BP, SD for all participants was 
(117, 11) mmHg systolic and (64, 7) mmHg diastolic. Mean 24-hour Pulse 
Wave Velocity (PWV), SD was (7, 0.8 ms-1). Based on the data accrued, the 
study had >98% power to detect a 5 mmHg difference in systolic BP (0.4 
standard deviations), a 4mmHg (0.5 standard deviations) difference in 
diastolic BP and a 0.4 ms-1 (0.5 standard deviations) difference in PWV 
between those with and those without SCT.  
Table 1 displays the characteristics of the participants according to SCT 
carrier status. The mean, SD 24-hour systolic and diastolic BP in subjects 
with SCT was (116, 11.5) and (64, 7) mmHg. In subjects without SCT the 
corresponding 24-hour BP values were (117, 11.4) and (64, 6.8) (p=0.8551 
and 0.9691 for comparison between SCT carriers and non-carriers). There 
were no statistically significant between-group differences in estimated 
glomerular filtration rate, clinic BP, clinic PWV and 24-hour PWV. There were 
no between-group differences in the prevalence of masked hypertension, 
white coat hypertension, or non-dipping status. Urinary sodium and potassium 
were 19.5 mmol/L (95%CI 1.4-37.6, p=0.0352) and 13.5mmol/L (CI 5.8-21.2, 
p=0. 0006) lower in SCT carriers than in non-carriers.  
Figure 2 displays distribution of 24-hour, daytime and nighttime blood 
pressures in study participants by SCT carrier status. All measures were 
similar for SCT carriers and non-carriers.  
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Table 2 displays the results of regression analyses examining whether SCT 
influenced 24-hour systolic and diastolic BP adjusted for age, sex, body mass 
index, glomerular filtration rate and pulse wave velocity. While age, sex, body 
mass index and glomerular filtration rate were all associated with 24-hour 
systolic BP, there was no association between SCT and 24-hour BP 
measures. Pulse wave velocity displayed the strongest association with both 
systolic and diastolic BP. Additional adjustment for urinary sodium and 
potassium levels made no material difference to the results. 
DISCUSSION 
It has previously been hypothesized that the excess risk of cardiovascular 
disease observed in African populations may be result from pleiotropic effects 
of genetic polymorphisms that protect them from common infections during 
childhood. An elegant example of this is variants of the APOL1 gene, which 
while reducing the risk of trypanosomiasis, increase the risk of hypertension 
associated chronic kidney disease.(33) Malaria has exerted the strongest 
known selective pressure on the human genome, SCT being prominent 
among the polymorphisms under positive selection.(34) Given the previously 
documented excess cardiovascular and renal events observed in both sickle 
cell disease and SCT, we hypothesized that individuals with SCT would have 
different BP compared to those without SCT.  
In this detailed study of BP phenotypes and arterial stiffness among children 
who were selected because they had had little exposure to malaria 
throughout childhood, we did not find any differences between those with and 
without SCT. Because the exposure measurement was a genetic trait 
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acquired at conception and the participants were ascertained to have 
remained in the same malaria-free environment since birth we believe that 
this study suggests that a direct effect of SCT on BP and indices of arterial 
stiffness is highly improbable within the first 11-17 years of life. 
Estimated glomerular filtration rate and urine albumin to creatinine ratio were 
the same in SCT carriers and non-carriers in this study. In a study conducted 
among blacks in the US showing increased renal events in SCT carriers, most 
participants were recruited at 45 years of age and above(8), much older than 
the population we recruited in this study. We however found significantly 
lower urine electrolyte levels in SCT carriers, which could be attributed to 
hyposthenuria (impaired urinary concentrating ability) that has previously 
been described in SCT.(35)  
 While we failed to detect any meaningful effect of SCT on BP and arterial 
stiffness, the results of this study do have important implications; first it seems 
unlikely that increased BP and arterial stiffness precede or are involved in the 
pathogenesis of cardiovascular and renal events in individuals with SCT. In 
view of this, studies of other biomarkers that could predict the development of 
chronic kidney disease in individuals with SCT are warranted. Because 
individuals with SCT form a significant proportion of the population in many 
developing as well as developed countries, early identification of risk factors 
in this sub-group of individuals could have significant population-wide 
benefits. 
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An alternative to the hypothesis that genetic variations protective against 
infectious diseases predispose to cardiovascular disease is that in some 
instances the infectious diseases themselves may have long-term 
consequences in survivors including the development of hypertension.(14) 
One robust way to test such hypotheses is by utilizing mendelian 
randomization techniques in which BP is compared in individuals with and 
without genetic variants that are associated with the infectious disease. An 
important prerequisite for using these variants is that they should not affect 
the outcome (BP) in the absence of the infectious disease (malaria). The 
results of this study suggest that SCT does not influence BP in the absence of 
malaria and can therefore be used as an instrumental variable in MR studies 
to test the malaria-high blood pressure hypothesis.(14) SCT is a particularly 
attractive candidate for such studies as it is relatively common in areas with 
malaria and displays a very strong protective effect against mild as well as 
severe malaria(2, 4) thus reducing sample size requirements for such studies. 
Confirmation of the hypothesis would represent a paradigm shift in 
understanding the pathogenesis of hypertension in many developing country 
settings where malaria is endemic.(36)  
A major strength of this population-based study was the use of ABPM, which 
is considered the reference standard for blood pressure measurement in 
children.(16) The study was well powered to detect very small differences in 
BP and PWV. We also used health and demographic surveillance system 
records that were prospectively collected in order to ascertain residence in a 
 14 
non-malaria zone, there being no better method of doing this in sub-Saharan 
Africa.  
A potential limitation of this study was the limited age range of subjects 
recruited, necessitated by the fact that there were no long-term residency 
records for older individuals. Most demographic surveillance systems in Africa 
were established in the late 1990’s to early 2000’s.(37) Recruiting older 
individuals would have compromised data on residency status in childhood, 
the period when malaria risk is highest. In addition, older subjects would be 
more likely to have acquired additional risk factors for hypertension, including 
chronic kidney disease that would have confounded the analyses. While BP 
differences are likely to be larger at older ages, it is known that differences in 
adult BP emerge in childhood(38, 39) and that childhood BP levels are 
predictive of adult BP.(40) The absence of even a small difference in carefully 
measured BP and arterial stiffness in our study of adolescents therefore 
suggests that it is very unlikely such differences would emerge in future. 
Although the study was well powered to detect differences in continuous 
variables such as mean nighttime and daytime BP, we were underpowered to 
detect differences in the prevalences of categorical variables such as masked 
hypertension and white coat hypertension. This could form the basis of future 
studies.  
An additional limitation of this study is the fact that as with many BP 
measurement devices, validation studies for the Arteriograph24™ have only 
been done in adults.(25) It is however unlikely that measurement error 
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significantly influenced the result, as the oscillometric principle used by the 
device has been validated in children and is particularly suited for pediatric 
ambulatory BP studies.(16, 41)  
Non-responders in this study were slightly older than those who participated, 
but the 0.6-year difference is unlikely to have significantly biased our results. 
We also observed no significant differences between those that provided 
acceptable ABPM data and those that did not suggesting that the data 
presented are representative of the larger population of individuals with sickle 
cell trait. 
In summary, we have demonstrated that the presence of sickle cell trait does 
not influence BP and arterial stiffness in Kenyan adolescents.  
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Table 1: Characteristics of study subjects according to sickle trait status, 
Nairobi, Kenya 2015-2016 
 
 
Characteristic 
SCT Noncarrier  (N=567) SCT Carrier (N=103) p-value 
No. % Mean (SD) No. % Mean (SD)  
Female sex 323 57  49 48  0.08 
Complete ABPM data 516 91  93 90  0.82 
White coat hypertensiona 23 44  3 3.2  0.59 
Masked hypertensiona 37 7.2  8 8.6  0.63 
Non dipping BP patterna 17 3  2 2  0.55 
Age, years   13.2 (2.2)   13.8 (2.3) 0.093 
BMIb   19 (3)   19 (3) 0.63 
MUAC, cm   23.2 (3.6)   23.5 (3.8) 0.41 
Hemoglobin, mg/dL   13.2 (1.5)   13.4 (1.6) 0.15 
White cell count   5.5 (1.5)   5.6 (1.3) 0.78 
Platelet count   310 (87)   305 (95) 0.64 
Serum sodium (mmol/L)   139 (6)   139 (6) 0.94 
Serum potassium (mmol/L)   4.9 (0.6)   5.0 (0.8) 0.093 
Socioeconomic status 
(MDPI score)   2.2 (1.3)   2.1 (1.3) 0.55 
Clinic BP, mmHg        
  Systolic   98 (11)   99 (13) 0.31 
  Diastolic   64 (8)   64 (9) 0.32 
Pulse wave velocity (ms-1)   7 (0.8)   7.1 (0.8) 0.26 
eGFR (mls/min/1.73m2)   110 (15)   108 (14) 0.12 
UACr    3.6 (18)   3.5 (8) 0.96 
Urine sodium (mmol/L)   136 (73)   119 (45) 0.031 
Urine potassium (mmol/L)   48 (31)   36 (23) 0.0001 
 
BMI=Body mass index; eGFR=estimated glomerular filtration rate; MDPI=multi-dimensional poverty 
index; MUAC=mid upper arm circumference; UACr=Urine albumin to creatinine ratio 
aData on white coat, masked hypertension and non-dipping pattern are based on the 609 
individuals that had complete ABPM data 
b BMI is calculated as Weight(kg)/height(m)2 
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Table 2: Predictors of mean 24-hour systolic and diastolic BPs among 
adolescents in Nairobi, Kenya, 2015-2016a 
 
Characteristic 
24-hour SBP 24-hour DBP 
β 95% CI p-value β 95% CI p-value 
Age, years 0.6 0.07, 1.1 0.027 0.008 –0.3, 0.3 0.96 
Male Sex 2.4 0.4, 4.3 0.016 –0.06 –1.3, 1.2 0.92 
BMIb 0.6 0.2, 1 0.001 0.2 –0.09, 0.4 0.21 
eGFR 
(mls/min/1.73m2) 0.08 0.01, 0.15 0.017 0.01 –0.03, 0.05 0.58 
PWV (ms-1) 2.8 1.6, 4.1 <0.001 2.7 1.9, 3.5 <0.001 
Sickle carrier 
status 0.1 –2.4, 2.6 0.923 0.4 –1.1, 2 0.58 
 
 SBP=systolic blood pressure; DBP= diastolic blood pressure; BMI=Body mass index; 
 eGFR=estimated glomerular filtration rate; PWV= pulse wave velocity 
aMultivariate analyses were conducted using data from participants that had complete 
Ambulatory BP Monitoring data (N=609) 
 bBMI is calculated as Weight(kg)/height(m)2 
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Figure 1 Legend: Study flow chart of participants in sickle trait–blood 
pressure study in Nairobi, Kenya 2015-2016. 
Figure 2 Legend: 24-hour ABPM measures by sickle cell trait (SCT) carrier 
status in Nairobi, Kenya 2015-2016. For each category of 24-hour, day and 
night measures, the plots on the left are for systolic blood pressure and those 
on the right are for diastolic blood pressure. Error bars represent 95% 
Confidence Intervals. 
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